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Abstract
Background: Melastoma malabathricum L. (family Melastomaceae) has been traditionally used as remedies against
various ailments including those related to pain. The methanol extract of M. malabathricum leaves has been proven
to show antinociceptive activity. Thus, the present study aimed to determine the most effective fraction among the
petroleum ether- (PEMM), ethyl acetate- (EAMM) and aqueous- (AQMM) fractions obtained through successive
fractionation of crude, dried methanol extract of M. malabathricum (MEMM) and to elucidate the possible mechanisms
of antinociception involved.
Methods: The effectiveness of fractions (100, 250 and 500 mg/kg; orally) were determine using the acetic acid-induced
abdominal constriction test and the most effective extract was further subjected to the hot plate- or formalin-induced
paw licking-test to establish its antinociceptive profile. Further elucidation of the role of opioid and vanilloid receptors,
glutamatergic system, and nitric oxide/cyclic guanosine phosphate (NO/cGMP) pathway was also performed using the
appropriate nociceptive models while the phytoconstituents analyses were performed using the phytochemical
screening test and, HPLC-ESI and GCMS analyses.
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Results: PEMM, EAMM and AQMM significantly (p < 0.05) attenuated acetic acid-induced nociception with the recorded
EC50 of 119.5, 125.9 and 352.6 mg/kg. Based on the EC50 value, PEMM was further studied and also exerted significant
(p < 0.05) antinociception against the hot plate- and formalin-induced paw licking-test. With regards to the
mechanisms of antinociception,: i) PEMM significantly (p < 0.05) attenuated the nociceptive action in capsaicin-
and glutamate-induced paw licking test.; ii) naloxone (5 mg/kg), a non-selective opioid antagonist, failed to
significantly (p < 0.05) inhibit PEMM’s antinociception iii) L-arginine (a nitric oxide precursor), but not NG-nitro-L-
arginine methyl esters (L-NAME; an inhibitor of NO synthase), methylene blue (MB; an inhibitor of cGMP), or their
respective combination, significantly (p < 0.05) reversed the antinociception of PEMM. Phytochemical analyses revealed
the presence of several antinociceptive-bearing bioactive compounds, such as triterpenes and volatile compounds like
oleoamide and palmitic acid. The presence of low flavonoids, such as gallocatechin and epigallocatechin, saponins and
tannins in PEMM might synergistically contribute to enhance the major compounds antinociceptive effect.
Conclusion: PEMM exerted a non-opioid-mediated antinociceptive activity at the central and peripheral levels via
the inhibition of vanilloid receptors and glutamatergic system, and the activation of NO-mediated/cGMP-independent
pathway. Triterpenes, as well as volatile oleoamide and palmitic acid, might be responsible for the observed
antinociceptive activity of PEMM.
Keywords: Melastoma malabathricum, Crude methanol extract, Fraction, Antinociceptive activity, Mechanisms of
antinociception, Non-opioid system, Vanilloid receptors, Glutamatergic system, NO-mediated/cGMP-independent
pathway
Background
Pain is one of the most common manifestations of many
diseases afflicting millions of people worldwide [1, 2]. It
is major symptom of various ailments that incessantly
producing severe physical and psychological distress for
many patients at the same time disrupting their quality of
life [3, 4]. In such situation, analgesics drugs are useful
due to these agents ability to relieve pain without produ-
cing a loss of consciousness. Currently, three major classes
of drugs are used in the pharmacological therapy of pain,
namely non-steroidal anti-inflammatory drugs (NSAIDs),
opioids and analgesic adjuvants, which target different
components of the peripheral and central nervous system
[5–7]. Unfortunately, the undesirable adverse effects such
as gastrointestinal damage, renal toxicity, sedation, tol-
erance and respiratory depression, always overshadowed
those drugs effectiveness and limited their uses [8, 9]. Due
to this issue, peoples living in many developing countries
in particular have been turning to natural products, par-
ticularly, those derived from medicinal plants/herbal med-
icines, as an alternative sources of pain-relieving agents
[10, 11]. The application of plant-based natural products
in the treatment of various ailments have been associated
with the assumption that natural products are at least
safe for consumption and cheaper than synthetically-
developed drugs [12, 13].
One of the plants that have been traditionally used
to treat pain is Melastoma malabathricum L. (family
Melastomaceae) [14]. Locally known to the Malay as
“Senduduk”, M. malabathricum has been used in the
Malay traditional medicines to treat ailments such as
stomach ulcers, dysentery and diarrhoea, those associated
with pain (i.e., toothache and stomachache), to accelerate
wound healing, for post-natal care and prevention of
scars from small pox infection, and postpartum remedy
[15–19]. Scientifically, the leaves of M. malabathricum
have been reported to exert no acute toxicity [20] and,
antibacterial [20, 21], antiviral [20], antioxidant [22],
cytotoxic [22], anti-inflammatory [23, 24], anticoagulant
[25], antiulcer [26], antidiarrheal [20], antinociceptive
[16, 24] and antipyretic [24] activities.
In order to justify the present antinociceptive study, it
is important to highlight on the previous reports related
to the antinociceptive activity of M. malabathricum. In
the two previous reports, the aqueous [24] and ethanol
[16] extracts of the leaves were used and only the role of
opioid receptors in modulating those extracts antinocicep-
tive activity was investigated. In addition, we have recently
published on the central and peripheral antinociceptive
potential of methanol extract of M. malabathricum
(MEMM), and reported on the involvement of vanilloid re-
ceptors, glutamatergic system and NO-mediated/cGMP-
independent pathway, but not opioid receptors, in the
modulation of MEMM antinociceptive activity [27]. Taking
these facts into account, the present study was designed to
determine the antinociceptive potential of several fractions
derived from MEMM, namely petroleum ether- (PEMM),
ethyl acetate- (EAMM,) and aqueous- (AQMM) extract,
and to determine the mechanisms of antinociception ex-
hibited by the most effective partition using various animal
models. Briefly, the fractions were screened using the acetic
acid-induced abdominal constriction test to select the most
potent fraction. The most potent fraction (in this case
PEMM) were then tested against the hot plate- and
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formalin-induced paw licking-test to establish its anti-
nociceptive profile and subjected to further investiga-
tion on the possible mechanisms of action involving the
role of opioid and vanilloid receptors, glutamate system




The leaves of M. malabathricum, collected and certified
by a botanist from the Institute of Bioscience (IBS),
Universiti Putra Malaysia (UPM), Serdang, Selangor,
Malaysia. A voucher specimen (ACP0017) has been de-
posited at the Herbarium of the Laboratory of Natural
Products, IBS, UPM, Malaysia.
Preparation of methanol extract of Melastoma
malabathricum (MEMM) leaves
This procedure was performed as described in detailed
by Zakaria et al. [27]. Briefly, 500 g of matured leaves
that have been air-dried for 1–2 weeks at room
temperature (27 ± 2 °C) were grinded into powder form.
The leaves were soaked in methanol in the ratio of 1:20
(w/v) for 72 h. These procedures were repeated three (3)
times using the same residue. After each soaking, the
supernatant was filtered using steel filter, cotton wools
and Whatman no. 1 filter papers, and the supernatant
collected from each extraction was pooled together. This
supernatant was then subjected to evaporation process
using a rotary evaporator at 40 °C under reduced pressure.
Preparation of fractions from MEMM
The petroleum ether (PEMM), ethyl acetate (EAMM)
and aqueous (AQMM) fractions were obtained from
crude dried MEMM via the standard solvent partitioning
methods as previously described by Sowndhararajan
et al. [28]. Briefly, dried MEMM (20 g) was dissolved in
1000 mL of methanol (1:20; w/v) followed by the addition
of 200 mL of distilled water. The suspension was then
added with 700 mL of petroleum ether and shake thor-
oughly before left for 24 h to settle down into two immis-
cible layers wherein the lower layer (petroleum ether
supernatant) was collected while the upper layer (aqueous
methanol supernatant) was subjected to repeat extraction
using new petroleum ether for another two times. On the
other hand, the undissolved upper layer was further parti-
tioned using ethyl acetate according to the procedures de-
scribed for petroleum ether. All petroleum ether and ethyl
acetate supernatants were collected and pooled together
before being rotary evaporated. Each supernatant was
evaporated under reduced pressure (204 Mbar) and
controlled temperature (40 °C) using a vacuum rotary
evaporator (Buchi Rotavapor® R210, Switzerland). In con-
trast, the remaining undissolved supernatant, which
represents the aqueous supernatant, was collected and sub-
jected to the freeze-drying process.
Phytochemical screening of the most effective fraction
(PEMM)
The phytochemical screening of the most effective fraction
(PEMM), which was determined following the antinoci-
ceptive evaluation using the abdominal constriction
test, was performed according to the standard screen-
ing tests described by Ikhiri et al. [29] but adopted by
Kamisan et al. [30]. The respective test, performed to
detect flavonoids, saponins, tannins, triterpenes, ste-
roids and alkaloids, was carried out based on the 100 mg
of crude extract or fractions.
HPLC analysis of the most effective fraction (PEMM) at
various wavelengths
The HPLC profile of MEMM has been published by
Mamat et al. [31]. The HPLC profile of the most effect-
ive fraction (PEMM) was established according to the
same methods [31]. Briefly, 10 mg of the respective frac-
tion was suspended in 1 ml methanol and then filtered
using the 0.45 μm pore size membrane filter. The fil-
tered extract was then analysed using the HPLC system
consisting of the Waters Delta 600 with 600 Controller
linked to a Waters 996 photodiode array detector (Mil-
ford, MA, USA) and a 5 μm column (Phenomenex
Luna; 4.6 mm i.d. × 250 mm) (Torrance, CA, USA). The
sample was eluted using a solvent system consisting of
0.1% aqueous formic acid (tagged as A) and acetonitrile
(tagged as B). The early condition was 95% A and 5% B
with a linear gradient attaining 25% B at t = 12 min. This
condition was retained for 10 min wherein at t =22 min,
B was decreased to 15%, which was then retained until t
= 30 min. The programme returned to the early solvent
composition at t = 35 min. Throughout the analysis
period, the flow rate was maintained at 1.0 ml/min
while the injection volume was maintained at 10 μl. The
column oven was positioned at 27 °C and the eluent was
monitored at 210, 254, 280, 300, 330 and 366 nm. The
retention time and UV spectra of major peaks were re-
corded and then analyzed. PEMM was then spiked with
a list of flavonoid-based compounds (served as the
standard), namely pinostrobin, hesperetin, flavanone, 4’,5,7-
trihydroxy flavanone, 2,4,4’-trihydroxy chalcone, querci-
trin, dihydroquercitin, fisetin, quercetin, rutin, querci-
trin, naringenin, silibinin, and genistein using the same
solvent system to detect their presence in the
respective fraction. The HPLC analysis was carried out
in the Laboratory of Phytomedicine, Medicinal Plants
Division, Forest Research Institute of Malaysia (FRIM),
Kepong, Malaysia.
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UHPLC-ESI Profile of the most effective fraction (PEMM)
The UHPLC system was performed on a Dionex 3000
UHPLC system acquired from Thermo Fisher Scientific
(USA) that consists of an auto-sampler equipped with a
column oven, a tray compartment cooler, and a binary
pump with built-in solvent degasser [32]. Samples (10 μL)
were injected and the chromatographic separation was
performed on a BEHC18UHPLC column, 100 mm× 2.5
μm, 1.7 μm (WATERS) at a flow rate of 0.3 mL/min. The
mobile phases used were (A) 0.1% formic acid in water
and (B) 0.1% formic acid in acetonitrile. The separation
was conducted using the following multistep gradient: ini-
tial conditions (t = 0 min) were 90% A and 10% B with a
linear gradient reaching 15% B at t = 3 min. The gradient
was then increased to 50% B in the next 7 min (t =
10 min) and further increased to 90% B for the next 2 min
(t = 12 min). Finally, the programme was returned to the
initial solvent composition at t = 17 min for the next ana-
lysis. The UHPLC system was coupled to a Linear Ion
Trap Orbitrap mass spectrometer (Q Exactive) from
Thermo Fisher Scientific (USA) equipped with an electro-
spray ionization (ESI) source. The mass detection was
performed in a range of 150–1500m/z. The ESI source
was operated in negative ion mode under the following
specific conditions: source voltage: 3.2 kV; sheath gas:
35 arbitrary units; auxiliary gas: 15 arbitrary units; sweep
gas: 10 arbitrary units; and capillary temperature: 320 °C.
Nitrogen (>99.98%) was employed as sheath, auxiliary,
and sweep gas. Instrument control and data acquisition
were performed with Chameleon 6.8 software and
Xcalibur 2.2 software (Thermo Fisher Scientific). The
UHPLC-ESI analysis was carried out in the Laboratory
of Phytochemistry Unit, Herbal Medicine Research
Centre, Institute for Medical Research, Jalan Pahang,
50588 Kuala Lumpur, Malaysia.
GC–MS analysis of MEMM and PEMM
GC-MS analysis of MEMM and PEMM were performed
using the Agilent GC system (Model no. Agilent
19091S-433) attached to the gas chromatograph-
interfaced to a mass spectrometer detector (GC-MSD)
equipped with a HP-5MS silica capillary column (30.0 m
X 250 μm X 0.25 μm nominal), composed of 5% phenyl
methyl siloxane. For GC-MS detection, an electron
ionization system with ionizing energy of 70 eV was
used. Helium gas (99.999%) was used as the carrier gas
at constant flow rate of 1 mL/min and an injection vol-
ume of 1 μL was employed (split ratio of 10:1); mode
Split-Splitless Inlet; Injector temperature 250 °C (pressure
10.39 psi); Ion-source temperature 280 °C. The oven
temperature was programmed from 100 °C (isothermal
for 2 min) and maximum oven configuration at 325 °C,
with an increase of 10 °C/min, to 200 °C, then 5 °C/min to
280 °C, ending with a 9 min isothermal at 280 °C. Mass
spectra were taken at 70 eV; a scan interval of 0.5 s and
fragments from 45 to 450 Da. Total GC running time was
35.50 min. The relative % amount of each component was
calculated by comparing its average peak area to the total
areas, software adopted to handle mass spectra and chro-
matograms was a Turbomass. For identification of com-
pounds, the interpretation on mass spectrum GC-MS was
conducted using the database of National Institute Stand-
ard and technology (NIST) having more than 62,000 pat-
terns. The spectrum of the unknown component was
compared with the spectrum of the known components
stored in the NIST library. The name, molecular weight
and structure of the components of the test materials were
ascertained.
Drugs and chemicals
The following reagents and drugs were used: methanol,
petroleum ether, and ethyl acetate (Fischer Scientific,
UK); dimethyl sulfoxite (DMSO), formalin, acetic acid,
morphine sulphate, acetylsalicylic acid (ASA), naloxone
(NLX), capsaicin, glutamate, capsazepine, L-arginine
(L-arg), NG-nitro-L-arginine methyl esters (L-NAME)
and methylene blue (MB) (Sigma, USA). The drugs were
prepared by dissolving them in the saline solution. The
MEMM was dissolved in the vehicle (10% DMSO) just be-
fore used. All solutions were administered in the volume
of 10 mL/kg.
Animals
Male Sprague Dawley (SD) rats (180–200 gm; 8–10 weeks
old) and male ICR mice (25–30 g; 5–7 weeks old) were
purchased from Che Nur Supplier, Selangor, Malaysia.
The animals were kept under room temperature (27 ±
2 °C; 70–80% humidity; 12 hrs light/darkness cycle) in
the Animal Holding Unit, Kulliyyah of Allied Health
Sciences, International Islamic University Malaysia (IIUM),
Pahang, Malaysia and were supplied with food and water
ad libitum up to the beginning of the experiments. Each
rats and mice were only used once. The animals were han-
dled in accordance with the current IIUM guidelines for
the care of laboratory animals and the ethical guidelines
for investigations of experimental pain in conscious ani-
mals [33]. The procedures in the present study were ap-
proved by the Animal Ethics Committee of International
Islamic University Malaysia [IIUM / IACUC Approval /
2016/ (9) (58)] and were performed in accordance with the
Integrated Centre for Research of Animal Care and Use
(ICRACU) guidelines. The number of animals and inten-
sity of noxious stimuli used were minimum and just at
the necessary amount to demonstrate the consistent ef-
fects of the treatments. In all experiments, data were col-
lected by a blinded, randomized and controlled design.
All the experiments were conducted between the 0930
and 1830 h to minimize the effects of environmental
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changes. All efforts were made to minimize animal suffer-
ing and to reduce the number of animals used.
Acute toxicity study
Acute toxicity study was performed according to the
guideline for testing of chemicals by adopting the OECD
No. 423 procedure [34]. According to this procedure,
the acute oral toxicity study was carried out using the
fixed dose approaches. Rats were divided into two groups
(n = 10) and fasted overnight. One group was then treated
with a single dose of 5000 mg/kg PEMM while the other
group was given vehicle (10% DMSO) (10 mL/kg) by gav-
age. Each animal was monitored at least once through the
first 30 min after the test solutions administration, inter-
mittently during the first 24 h and daily afterward for
14 days. Food and water were supplied ad libitum. The
mortality, body weight and behavioral screening were
documented daily within the 14 days observation. Any
survived rats were euthanized and subjected to the
macroscopic analysis. The vital organs were collected,
weighted and then fixed in 10% formalin for microscopic
analysis.
Antinociceptive studies
Acetic acid-induced abdominal constriction test
The acetic-acid-induced abdominal constriction test
was performed according to the method described by
Zakaria et al. [26] with slight modification. Male ICR
mice were placed in the 10 L glass beaker as observation
chamber for 20 min prior to the experiment to adapt to
their surroundings. The mice (n = 6) were pre-treated or-
ally (p.o) with 10% DMSO (negative control), 100 mg/kg
ASA (positive control), or PEMM, EAMM, or AQMM
(100, 250, and 500 mg/kg). 60 min after the respective test
solution administration, the mice were injected via intra-
peritoneal (i.p) route with 0.6% acetic acid (10 mL/kg).
The animals were immediately placed individually into the
observation chamber and 5 min were allowed to elapse.
The abdominal constriction resulting from the injection
of acetic acid consists of constrictions of the abdominal
together with a stretching of at least one hind limb. The
number of abdominal constrictions produced in these ani-
mals was counted cumulatively for 25 min. Antinocicep-
tive activity, indicated by the reduction in the mean of the
number of abdominal constrictions in the test groups
compared to the control group, was calculated as the per-
centage inhibition of abdominal constrictions (percentage
of inhibitory level) using the following formula: (mean of
[(control - test group)/control group] X 100%).
Hot plate test
The hot-plate test was used to measure response latency
according to the method described by Zakaria et al. [26]
with some modifications. The temperature of the metal
surface (Hotplate Analgesia Meter, Columbus Instru-
ments, Model: 144-E52) was set at 50 ± 0.2 °C. The
time(s) elapsed between placement until the occurrence
of discomfort reactions (licking paws or jumping) was
recorded as the response latency time. The mice were
selected a day prior to the test on the basis of their
reactivity, and only those with response latencies of
5–7 s. were used in the study. The mice (n = 6) were
pre-treated (p.o) with 10% DMSO (negative control),
5 mg/kg morphine (positive control or reference drug), or
PEMM (100, 250, and 500 mg/kg). Sixty minutes after the
respective test solution administration, the mice were
placed on the heated metal surface with the arbitrary cut-
off time of 20 s. This cut-off time was adopted and defined
as complete analgesia as well as to avoid tissue injury. The
latency to a discomfort reaction was recorded before and
at 60, 90, 120, 150, 180, 210 min after the p.o. administra-
tion of test solutions. The prolongation of the latency
times compared with the values of the controls was used
for statistical comparison.
Formalin-Induced paw licking test
The formalin test was performed as described by Zakaria
et al. [26] but with slight modifications. Pain was in-
duced by injecting 50 μL of 5% formalin in the intra-
plantarly (i.pl.) into the ventral surface of the right hind
paw. Rats (n = 6) were administered p.o. with 10% DMSO
(negative control), 5 mg/kg morphine or 100 mg/kg ASA
(both act as the positive controls), or PEMM (100, 250,
and 500 mg/kg) 60 min prior to the formalin injection.
Immediately after the phlogistic agent administration, the
rats were individually placed into 10 L glass beaker as ob-
servation chamber. The amount of time that the animal
spent licking, or biting the injected paw, considered as an
indicator of pain, was recorded for the duration of 30 min
in two phases, known as the early (0–5 min) and late
(15–30 min) phases.
Analysis of the possible mechanism of antinociceptive
action of PEMM
Investigation on the role of vanilloid receptors using the
capsaicin-induced paw licking test
To investigate the role of vanilloid or TRPV1 receptors
in the modulation of MEMM antinociceptive action, the
procedure described by Mohd Sani et al. [35] was adopted
with slight modifications. Rats were pre-treated orally with
10% DMSO, capsazepine (Capz, 0.17 mmol/kg) or PEMM
(100, 250, and 500 mg/kg) 60 min before capsaicin
(1.6 ug/paw, 20 μL) administration via i.pl. route into
the ventral surface of the right hind paw. Immediately
after the phlogistic agent administration, the rats were
individually placed in a transparent glass cage observa-
tion chamber and observed individually for 5 min. The
amount of time the animals spent licking the injected
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paw was recorded with a chronometer and was con-
sidered as an indication of nociception.
Investigation on the role of glutamatergic system using the
glutamate-induced paw licking test
To study the role of glutamatergic system in the modu-
lation of PEMM antinociceptive action, the procedure
described by Mohd Sani et al. [35] was performed with
slight modifications. Rats were pre-treated orally with
10% DMSO, 100 mg/kg ASA or PEMM (100, 250, and
500 mg/kg) 60 min prior to glutamate injection. A volume
of 20 μL of glutamate (10 μmol/paw; in normal saline)
was injected via i.pl route into the ventral surface of the
right hind paw. Immediately after the phlogistic agent
administration, the rats were individually placed in a
transparent glass cage observation chamber and observed
individually from 0 to 15 min. The amount of time the
animals spent licking or biting the injected paw was re-
corded with a chronometer and was considered as an
indicator of nociception.
Investigation on the involvement of opioid receptors system
using the hot plate and formalin-induced paw licking tests
To determine the role of opioid receptors in the modu-
lation of PEMM antinociceptive activity, a separate pro-
cedure described by Mohd Sani et al. [35] was adopted
with slight modifications. Four groups of animals (n = 6)
were pre-treated (i.p.) with a non-selective opioid antag-
onist, naloxone (5 mg/kg; i.p.) for 15 min followed by
the oral administration of 10% DMSO or PEMM
(500 mg/kg). Sixty minutes later, the animals were sub-
jected to the hot plate test and formalin test.
Investigation on the involvement of nitric oxide/cyclic-
guanosine monophosphate (NO/cGMP) pathway using the
abdominal constriction test
To determine the role of nitric oxide/cyclic-guanosine
monophosphate (NO/cGMP) pathway in the modulation
of PEMM antinociceptive activity, the method described
by Mohd Sani et al. [35] was adopted with slight modi-
fications. Mice (n = 6) were pre-treated with 20 mg/kg
L-arginine, L-NAME, MB, or their respective combin-
ation (L-arginine with L-NAME or L-arginine with MB)
followed 5 min later by treatment with 10% DMSO or
PEMM (500 mg/kg), respectively. Sixty minutes after the
administration of test solutions, the mice were injected
(i.p) with 0.6% acetic acid.
Statistical analysis
The data from the antinociceptive studies (n = 6) were
expressed as means ± standard error of mean (S.E.M)
and analyzed by one or two-way analysis of variance
(ANOVA) followed by the respective Dunnett’s post hoc
test, or Bonferroni post-test, unless otherwise stated.
The different between means of treated and a control
group was considered significant at P < 0.05. The ED50
(effective dose producing a 50% inhibition in relative to
control value) value for all partitions following the ab-
dominal constriction study were determined using the
GraphPad Prism Software 5.0 (GraphPad Prism, USA).
The calculated ED50 and percentages of inhibition were
used to determine the most effective partition to be used
in the further antinociceptive studies.
Results
Phytochemical screening of PEMM
The crude MEMM has been reported elsewhere to con-
tain flavonoids, triterpenes, tannins, saponins and steroids.
In comparison to MEMM, PEMM showed strong pres-
ence of triterpenes and steroids but low presence of flavo-
noids, tannins and saponins. No alkaloids were detected
in MEMM or PEMM (Table 1).
HPLC profiling of PEMM at different wavelength
The HPLC profile of PEMM measured at the wavelength
of 254 and 366 nm is shown in Fig. 1, respectively. At
254 nm, three major peaks were detected in PEMM at
the retention time (RT) of 18.946, 20.608 and 23.063 min
while at 366 nm only two major peaks were detected in
PEMM at the retention time (RT) of 20.630 and
23.064 min.
Further analysis via spiking with standard flavonoid-
based compounds available in our laboratory collection
demonstrated that none of the pure flavonoid-based stan-
dards (e.g. pinostrobin, hesperetin, flavanone, 4’,5,7-trihy-
droxy flavanone, 2,4,4’-trihydroxy chalcone, quercitrin,
dihydroquercitin, fisetin, quercetin, rutin, quercitrin, nar-
ingenin, silibinin, and genistein) were detected in PEMM.
Figure 2 show that, at least, rutin’s peak, which is the clos-
est to one of the peak of PEMM, did not perfectly match
the peak with RT of 20.630 min.
Table 1 Phytochemical screening of semi-purified PEMM and
comparison to crude MEMM








For flavonoids, tannins, triterpene and steroids - + : weak colour; ++ : mild
colour; +++ : strong colour
For saponins −+: 1 – 2 cm froth; ++: 2 – 3 cm froth; +++: > 3 cm froth
For alkaloids: − +: negligible amount of precipitate; ++: weak precipitate; +++:
strong precipitate
aAdapted from report made by Mamat et al. [31]
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UHPLC-ESI profiling of PEMM
The fraction of M. malabathricum, PEMM, was ana-
lyzed based on the accurate mass data of the molecular
ions, in which ions detected were tentatively identified
by their generated molecular formula using the data ana-
lysis software (Xcalibur) that provided list of possible
elemental formulas. These findings were compared to-
gether with the standard flavonoids available in the la-
boratory and further supported by the thorough survey
of the literature. The widely accepted accuracy threshold
for confirmation of elemental compositions was estab-
lished at 5 ppm. The UHPLC-ESI analysis of PEMM
revealed the presence of only two very small peaks indicat-
ing the presence of very small concentration of phenolic
compounds, which have been identified as gallocatechin
and epigallocatechin (Fig. 3).
GC-MS profiles of MEMM and PEMM
GC-MS spectra profile of crude extract (MEMM) and
the most effective fraction (PEMM) are presented in the
Fig. 4a and b while the identified volatile compounds are
presented in Tables 2 and 3, respectively. Twenty nine
volatile compounds were identified in MEMM with oleic
acid amide (43.99%), 3-methylquinoline (7.84%) and
propanoic acid (5.78%) being the three major volatile
compounds (Table 2). Table 3 shows the volatile com-
pounds present in PEMM wherein four major volatile com-
pounds were detected, namely, oleic acid amide (11.54%),
palmitinic acid (6.95%), methyl-25-homocholesterol
(10.06%), linolenic acid methyl ester (5.69%) and phthalic
acid (5.90%).
Acute toxicity effect of PEMM
All animals, either those that received PEMM or vehicle,
exhibited a rise in body weight at weeks 1 and 2 in com-
parison to day 0. No changes in the behavioral pattern,
mortality, or food and water intake behavior were de-
tected among the animals were detected during the dur-
ation of experimentation. Moreover, there is no
significant changes detected in the relative weight of vital
organs, which was supported by the microscopic analysis
that shows no signs of toxicity (data not shown). Based
on these findings, PEMM was suggested to possess an
LD50 that is greater than 5000 mg/kg body weight.
Antinociceptive profile of fractions assessed using the
abdominal constriction test
The antinociceptive profile of PEMM, EAMM and AQMM
assessed by the acetic acid-induced abdominal constriction
test in mice is shown in Fig. 5. Pre-administration of
Fig. 1 The HPLC profile of PEMM at 254 nm and 366 nm
Fig. 2 The HPLC profile of PEMM demonstrated the absence of rutin
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PEMM, EAMM and AQMM (100, 250 and 500 mg/kg,
p.o) significantly (p < 0.05) reduced the number of abdom-
inal writhes induced by acetic acid in a dose-dependent
manner. From the data obtained, PEMM and EAMM
exerted almost similar antinociceptive efficacy but based
on the calculated ED50 values, PEMM (ED50 = 119.5 mg/
kg) was considered to be more effective than EAMM
(ED50 = 125.9 mg/kg). Thus, PEMM was chosen for fur-
ther antinociceptive studies.
Antinociceptive profile of PEMM assessed using the
hot-plate test
The antinociceptive profile of PEMM assessed using the hot
plate test is shown in Table 4. PEMM demonstrated a signifi-
cant (p < 0.05) antinociceptive activity in a dose-dependent
manner indicated by the increase in the latency of time
spend on the thermal-induced hot plate apparatus. PEMM,
at 100 mg/kg, was significantly effective only at the interval
of 60 and 90 min after the extract administration while, at
the doses of 250 and 500 mg/kg, PEMM exerts its antinoci-
ceptive activity until the end of the experiment. Interestingly,
the antinociceptive efficacy of PEMM was comparable to
that of 5 mg/kg morphine (a reference antinociceptive drug).
Antinociceptive profile of PEMM assessed using the
formalin-induced paw licking test
The antinociceptive potential of PEMM against the
formalin-induced paw licking test is shown in Fig. 6a
and b. Pre-treatment with PEMM caused significant (p <
0.05) reduction in the latency of time spends to lick the
formalin-injected paw in a dose-dependent manner.
Interestingly, the ability of PEMM to attenuate nocicep-
tion induced by formalin can be seen in both the early
and late phases, a characteristic also seen with 5 mg/kg
morphine, but not 100 mg/kg ASA.
Mechanisms of antinociceptive activity of PEMM
Involvement of vanilloid receptors in the antinociceptive
activity of PEMM
From the results obtained, PEMM, at all doses, caused a
significant (p < 0.05) and dose-dependent inhibition of the
capsaicin-induced neurogenic nociception (Fig. 7). Admin-
istration of capsazepine (vaniloid receptors’ antagonist), at
0.17 mmol/kg, significantly (p < 0.05) produced approxi-
mately 55.3% inhibition against capsaicin-induced nocicep-
tion, which was comparable to that of 500 mg/kg PEMM
(60.5%).
Involvement of glutamatergic system in the antinociceptive
activity of PEMM
From the results obtained, all doses of PEMM significantly
(p< 0.05) reduced the latency of paw licking due to glutamate-
induced nociception (Fig. 8). Administration of 100 mg/kg
ASA significantly (p< 0.05) produced approximately 74.1%
inhibition against glutamate-induced nociception, which
was comparable to that of 500 mg/kg PEMM (66.2%).
Fig. 3 The HPLC-ESI profile of PEMM demonstrated the presence of low content of flavonoid-based compounds, namely gallocatechin
and epigallocatechin
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Fig. 4 a The GCMS profile of MEMM. b The GCMS profile of PEMM
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Involvement of opioid receptors in the antinociceptive
activity of PEMM
The results show that naloxone failed to significantly
interfere with the antinociceptive activity of PEMM in
both the hot plate and formalin-induced paw licking
tests (Table 4 and, Fig. 6a and b, respectively).
Involvement of NO/cGMP pathway in the antinociceptive
activity of PEMM
Figure 9a shows that: i) pre-treatment with 20 mg/kg
L-arginine alone did not change the nociceptive intensity
induced by acetic acid; ii) pre-treatment with 20 mg/kg
L-NAME alone significantly (p < 0.05) reduced the noci-
ceptive effect of acetic acid, and; iii) a combination of
L-arginine and L-NAME (L-arginine + L-NAME) alone
reversed the antinociceptive effect of L-NAME when
given alone. On the other hand, pre-challenging PEMM
with: i) L-arginine significantly (p < 0.05) reversed, but
did not block, the antinociceptive activity of PEMM; ii)
L-NAME did not significantly change the antinociceptive
intensity of PEMM, and; iii) a combination of (L-arginine +
L-NAME) significantly (p < 0.05) reversed, but did not in-
hibit, the antinociceptive activity of PEMM.
Figure 9b shows that: i) pre-treatment with MB alone
induced significant (p < 0.05) antinociceptive activity, and;
ii) pre-treatment with a combination of L-arginine and
MB (L-arginine +MB) alone also demonstrated signifi-
cant (p < 0.05) antinociceptive activity. Conversely,
pre-challenging PEMM with MB or a combination of
(L-arginine +MB) failed to significantly (p < 0.05) change
the antinociceptive intensity developed following earlier
pre-treatment with MB.








1. 4.83 2.28 2-Furancarboxaldehyde
2. 5.50 1.53 α-L-Galactopyranoside
3. 6.30 1.71 2-Methyl-L-mannomethylpyranoside
4. 6.83 2.28 Pyrogallic acid
5. 9.00 2.68 α-D-Glucopyranoside
6. 9.06 0.58 Methyl β-d-Galactopyranoside
7. 9.13 1.18 β-D-Glucopyranoside
8. 9.22 1.87 β-D-Ribopyranoside
9. 9.25 2.82 Galactopyranoside
10. 10.22 1.62 Pyridine
11. 12.49 3.38 Palmitic acid
12. 12.88 2.88 Palmitinic acid
13. 13.03 1.26 Myristic acid amide
14. 14.11 0.87 Linoleic acid
15. 14.18 2.08 Linolenic acid
16. 14.37 0.56 Stearic acid methyl ester
17. 14.54 1.34 Oleic acid
18. 14.58 0.54 Pentadecanoic acid
19. 14.76 2.90 Oleic acid amide
20. 14.92 2.85 N-tetradecanoic acid amide
21. 15.56 0.40 Heptanamide
22. 15.63 0.52 Erucylamide
23. 16.54 43.99 Oleic acid amide
24. 16.63 0.56 Pentanimidic acid
25. 17.63 1.62 Dodecanedoic acid-dimetyl ester
26. 18.54 0.74 5,6-methylenedecane
27. 19.16 7.84 3-Methylquinoline
28. 19.21 5.78 Propanoic acid
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13. 16.10 1.03 Arachidic acid methyl ester
14. 16.48 11.54 Oleoamide
15. 16.62 1.53 Trifluoroacetic acid
16. 16.70 2.17 hexanedioic acid Diisooctyl adipate
17. 17.92 2.23 1,2-Benzenedicarboxylic acid
18. 20.23 2.16 2-Acetyl-N-methylaniline
19. 20.72 5.90 Phthalic acid
20. 21.00 1.69 2-methyl-Benzothiazole
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Discussion
In an attempt to contribute to the discovery of alternative/
new pain relieving agents with lack of unwanted side ef-
fects from medicinal plants, further antinociceptive inves-
tigations were performed on Melastoma malabathricum
leaves. The present study was a continuation to our re-
cently published report on the antinociceptive activity of
methanol extract of M. malabathricum (MEMM) [27].
The justification for performing this experiment can be re-
lated to the phytoconstituents of methanol extract. Metha-
nol is classified as a polar solvent due to the presence of
hydroxyl (−OH) group. However, there is also methyl
group presence in methanol, which is sort of non-polar.
Due to the presence of both polar and non-polar compo-
nents in methanol, compounds that dissolve in water and
oils equally well including their intermediates dissolves
well in methanol. According to Ahmad et al. [36], the abil-
ity to extract various types of compounds using a solvent
like methanol is parallel to the ability to increase extract’s
yield. Moreover, Caunii et al. [37] reported that methanol:
i) can give higher concentrations of bioactive molecules
from plants, and; ii) is the best solvents for extraction of
different classes of phenolic compounds. These reports
might be used to explain the high total phenolic content
(TPC) value of MEMM [31] and supported the UHPLC
analysis of MEMM, which demonstrated the presence of
various flavonoids-based bioactive compounds (e.g. gal-
locatechin, epigallocatechin, catechin, chlorogenic acid,
caffeic acid, quercetin, quercetin-3-O-glucoside, p-coumatic
and hesperidin). In addition to these, the phytochemicals
Fig. 5 Antinociceptive activity of PEMM, EAMM and AQMM assessed using the acetic acid-induced abdominal constriction test in mice




Latency of discomfort(s) at respective time interval (min)
0 min 60 min 90 min 120 min 150 min 180 min 210 min
10% DMSO - 6.97 ± 0.22 6.97 ± 022 6.90 ± 0.23 6.15 ± 0.15 6.92 ± 0.23 6.88 ± 0.29 6.35 ± 0.17
Morphine 5 5.77 ± 0.15 17.37 ± 1.03a 18.25 ± 0.74a 16.52 ± 1.22a 13.67 ± 1.43a 11.22 ± 1.11a 10.48 ± 0.58a
PEMM 100 6.89 ± 0.11 9.43 ± 0.36a 9.67 ± 0.22a 7.68 ± 0.35 7.36 ± 0.20 7.51 ± 0.17 6.95 ± 0.20
250 6.36 ± 0.27 9.60 ± 0.24ab 10.30 ± 0.30ab 10.41 ± 0.60ab 9.82 ± 0.44ab 9.22 ± 0.20a 7.97 ± 0.20a
500 6.36 ± 0.08 11.92 ± 0.91ab 13.40 ± 0.48ab 13.38 ± 0.56ab 12.43 ± 0.91a 10.33 ± 0.27a 9.13 ± 0.08a
Naloxone (NLX) 5 6.38 ± 0.27 6.43 ± 0.41 5.98 ± 0.46 6.10 ± 0.21 5.93 ± 0.68 6.13 ± 0.58 5.67 ± 0.54
Naloxone + PEMM 5 + 500 6.71 ± 0.20 11.62 ± 0.72 13.40 ± 1.00 12.87 ± 1.00 12.00 ± 0.56 10.64 ± 0.27 8.88 ± 0.29
aData differed significantly (P < 0.05) when compared against the control (10% DMSO-treated) group
bData differed significantly (P < 0.05) when compared against the 5 mg/kg morphine-treated group
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screening of MEMM also demonstrated the high presence
of triterpenes, saponins and tannins [31]. Taking into
account the presence of various classes of bioactive
compounds with different polarity [27, 31], further in-
vestigations need to be carried out before the bioactive
compound(s) responsible for the observed antinocicep-
tive activity could be determined. Thus, the present
study was designed to separate the bioactive compounds
into non-polar, moderate polar (intermediate) and polar
compounds by successive partitioning of MEMM using
several solvents with different polarity to obtain the re-
spective PEMM, EAMM and AQMM. It is worth-
mentioning that this attempt was performed based on
suggestion made by Caunii et al. [37] that if the methanol
extract expressed remarkable biological activity, further
analysis towards isolation and purification of the respon-
sible bioactive compounds should be carried out.
In the present study, the fractions (PEMM, EAMM
and AQMM) were first subjected to the antinociceptive
study using the abdominal constriction test to assess the
antinociceptive efficacy of each extract and the results
obtained show that PEMM and EAMM exerted the anti-
nociceptive activity in almost similar intensity. However,
PEMM was chosen for further antinociceptive study based
on its lower ED50 value in comparison to the EAMM.
PEMM was also found to exert antinociceptive activity
against the hot plate test and both phases (early and late)
of the formalin-induced paw licking test. With regards to
the mechanisms of antinociception of PEMM: i) PEMM
inhibited the capsaicin- and glutamate-induced paw
Fig. 6 Antinocicpetive activity of PEMM assessed at the a early phase and b late phase of the formalin-induced paw licking test in rats
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licking test suggesting the involvement of vanilloid re-
ceptors and glutamatergic system, respectively; ii) na-
loxone (a non-selective opioid antagonist) failed to
reverse PEMM antinociceptive activity indicating the
non-involvement of opioid receptor system, and; iii)
L-arginine (a nitric oxide precursor), but not L-NAME
(an inhibitor of NO synthase), MB (an inhibitor of
cGMP), or their respective combination, reversed the
antinociceptive activity of PEMM suggesting the involve-
ment of NO-mediated/cGMP-independent pathway.
The acetic acid-induced abdominal constriction test has
been associated with the activation of peripheral nocicep-
tive processes [38–40] and induction of acute peritoneal
inflammation (localized inflammatory response) by the
phlogistic agent. Moreover, the latter process occurs via
the action of cyclooxygenase (COX) and increase in pros-
taglandins (PGE2 and PGF2α) biosynthesis [35, 40–42].
Hence, any agents capable of inhibiting the action of COX
or restricting the synthesis of PGEs could be good anti-
nociceptive agents as seen with the peripherally acting
non-steroidal anti-inflamamtory drugs (NSAIDs), ASA
[42, 43]. Interestingly, PEMM also attenuated the acetic-
acid-induced peripheral nociception indicating the pres-
ence of analgesic principles with ability to attenuate
inflammatory-mediated pain [44] by acting, partly, to
inhibit the action of COX and/or synthesis of PGEs as
described earlier. Unfortunately, the abdominal constric-
tion test is considered: i) a non-specific test due to its in-
ability to provide information on the peripheral and/or
central nociceptive level inhibited by PEMM [45] and ii)
to have poor specificity as it can give false positive re-
sults when use to test certain non-analgesic drugs such
as muscle relaxants [46]. Thus, the applications of
other nociceptive models are necessary before the final
Fig. 8 Antinociceptive activity of PEMM assessed using the glutamate-induced paw licking test in rats
Fig. 7 Antinociceptive activity of PEMM assessed using the capsaicin-induced paw licking test in rats
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Fig. 9 a Effect of L-arginine, L-NAME and their combination on PEMM antinociception as assessed by acetic acid-induced abdominal constriction
test. b: Effect of L-arginine, MB and their combination on PEMM antinociception as assessed by acetic acid-induced abdominal constriction test
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conclusion on the possible mechanisms of action adopted
by PEMM could be drawn. In the present study, the hot
plate test and formalin-induced paw licking test were
adopted to further determine the antinociceptive activity
of PEMM.
The hot plate test is selective toward the centrally-acting
analgesic drugs such as opioid analgesics (such as mor-
phine) [47] and measures the complex feedback to a
non-inflammatory, acute nociceptive input resulting
from a brief exposure to a noxious thermal stimulus. In
the present study, PEMM successfully attenuated the
thermal-induced nociceptive effect suggesting the ex-
tract ability to inhibit the central nociceptive center.
Another model of nociception, the formalin-induced
paw licking test, is widely used to evaluate the ability of
extracts/compounds to affect the peripheral and/or cen-
tral nociceptive pathways. Being a model of persistent/
continuing pain, the formalin test displays a biphasic re-
sponse following the administration of formalin known
as the early and late phases, which represents the respect-
ive centrally- and peripherally-mediated nociception [48].
Drugs acting at the central level (such as morphine) in-
hibit both phases of the formalin test in comparison to
drugs acting at the peripheral level (such as ASA), which
inhibit only the late phase. In the present study, PEMM
was also found to inhibit both phases of the formalin-
induced nociception, thus, further suggesting its ability to
block the central nociceptive center. Overall, findings
obtained from the three nociceptive assays implied that
PEMM contains non-polar bioactive compound(s) with
ability to modulate the central and peripheral nociceptive
mechanisms. PEMM was also able to attenuate both the
non-inflammatory- and inflammatory-mediated pain.
The roles of opioid receptors in the regulation of modu-
lation of nociceptive processing have been demonstrated
in many previous studies [49, 50]. However, the effective-
ness of opioid analgesics (such as morphine) has been
overshadowed by many adverse side effects (e.g. respira-
tory depression, vomiting, nausea, constipation, tolerance,
and dependence). This is further worsening by the fact
that prolongs use of morphine leads to the development
of analgesic tolerance, which requires dosage increases to
maintain its analgesic effect. This is problematic since dos-
age increases also amplify the frequency and severity of its
side effects. Therefore, searching or developing new an-
algesics without these side effects is imperative. The
non-opioid activity exerted by PEMM despite its ability
to act centrally and peripherally as seen with morphine
seems to be an added advantage when discussed in con-
tact of finding new and alternative analgesics with un-
wanted side effects.
Furthermore, the roles of vanilloid receptors, also known
as transient receptor potential cation channel subfamily
V member 1 (TRPV1), and glutamatergic system in the
regulation of nociceptive transmission have been reported
elsewhere [51, 52]. Vanilloid receptors, are activated by
capsaicin, an active ingredient in hot chili peppers, and se-
lectively acting on neurones within the peripheral and
central nervous systems [53, 54]. The present study shows
that PEMM possessed antagonistic effect against the
vanilloid receptors based on its ability to inhibit nocicep-
tive transmission modulated via the vanilloid receptors.
This observation was supported by earlier researches that
reported on the ability of antagonists of TRPV1 receptors
to exert antinociceptive activity and, to attenuate inflam-
matory- and neuropathic-pain [51, 52].
On the other hand, the glutamatergic system (glutamate
and glutamatergic receptors) has also been acknowledged
to be vital in the peripheral, spinal, and supraspinal
nociceptive neurotransmission [55]. Activation of gluta-
matergic receptors, to a great extent, is interceded by
both N-methyl-D-aspartate (NMDA) and non-NMDA
receptors, and the presence or absence of NO and NO-
related substances [56]. Furthermore, earlier report by
Dickenson and Sullivan [57] shows that the antagonists
of NMDA receptor block the spread of pain sensation
and lessen the hyperexcitability of spinal cord neurons
generated by C-fiber stimulation. In line with the above-
mentioned reports, the present study revealed the ability
of PEMM to attenuate the glutamate-induced nociceptive
effect, which could possibly be achieved by acting as
an NMDA receptor antagonist or by modulating the
NO-mediated pathway. Interestingly, the next findings
did support the latter claim that PEMM attenuated
glutamate-induced nociception via the NO-mediated
pathway.
The role of NO/cGMP pathway in the modulation of
nociceptive transmission at the PNS and CNS levels has
been well documented [58, 59]. In the earlier discussion
we have highlighted that PEMM exerts a characteristic
of morphine by acting at the central and peripheral
nociceptive levels. Since morphine also exhibits antino-
ciceptive activity via the NO/cGMP pathway activation
[60, 61], there is a need to also evaluate the involvement
of NO/cGMP pathway in the antinociceptive activity of
PEMM. In the present study, PEMM antinociception
was reversed by high level of NO (due to presence of
L-arginine alone) but was not affected by low level of
NO (due to the presence of L-NAME alone). This ob-
servation is concurrent with suggestion that the effect
of NO on nociceptive response depends on dosage
levels and the rate and timing of its release [58, 59]. As
mentioned earlier, the presence of NO activates soluble
guanylyl cyclase (sGC) leading to increase in cGMP
levels, which in turn affects pain and analgesia. The
role of cGMP pathway in the modulation of nocicep-
tive process was observed when MB, an inhibitor of
cGMP pathway, exerted antinociceptive activity when
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given alone. However, MB failed to affect the antinoci-
ceptive activity of PEMM suggesting that the antinoci-
ceptive activity of PEMM did not involved modulation
of cGMP pathway. This finding also indicates that
PEMM might trigger antinociceptive activity via the
NO-dependent/cGMP-independent pathway. Moreover,
since opioids like morphine induced antinociceptive ac-
tivity via the NO/cGMP pathway, it seems reasonable
to suggest that the non-opioid-acting PEMM triggered
antinociceptive activity via a different pathway mediated
by NO, but independent of cGMP activity (NO-mediated/
cGMP-independent pathway). The role of NO-dependent/
cGMP-independent pathway in the modulation of antino-
ciceptive activity has been reported by Morioka et al. [62]
and could be used to support the present observations.
Previous phytochemical screening of MEMM demon-
strated the strong presence of flavonoids, triterpenes, tan-
nins, saponins and steroids, but no alkaloids in the leaves
of M. malabathricum [31]. On the other hand, the phyto-
chemical screening of PEMM demonstrated the strong
presence of only triterpenes with low presence of fla-
vonoids, tannins and saponins. The low presence of fla-
vonoids in PEMM particularly was further supported by
the HPLC and UHPLC-ESI analyses. In the former ana-
lysis, only two peaks were detected at 366 nm, which upon
comparison of retention time and chromatogram against
10 pure flavonoids did not match to any of them, thus,
suggesting their absence in PEMM. In the latter analysis,
only two small peaks were detected and identified as gallo-
catechin and epigallocatechin, respectively. In support of
the phytochemical screenining of PEMM, Nurestri et. al.
[63] isolated three pentacyclic triterpenoids, namely urso-
lic acid, 2-hydroxyursolic acid and asiatic acid in addition
to glycerol-1,2-dilinolenyl-3-O-β-D-galactopyranoside and
glycerol 1,2-dilinolenyl- 3-O-(4,6-di-O-isopropylidene)-β-
D-galactopyranoside from MEMM while partitioning of
MEMM using hexane (HEMM), which is also grouped as
a non-polar solvent like petroleum ether, lead to the
isolation of a triterpene (α-amyrin) and two amides
(patriscabatrine and auranamide) [25]. Based on the
presence of triterpene-based compounds as described
above, further explanation with regards to the possible
mechanisms of antinociception of PEMM could be plaus-
ibly suggested. For examples; i) 3β, 6β, 16β-trihydroxylup-
20(29)-ene inhibited glutamate- and formalin-induced
nociceptive models, and exert antinociceptive activity that
is dependent on the opioid and serotonergic systems
[64]; ii) siaresinolic acid reduced the acetic acid-induced
nociceptive response via the activation of non-opioid
system and ATP–dependent potassium channels [65];
iii) 24-hydroxytormentic acid inhibited the acetic acid-
and formalin-, but not thermal-induced nociception via
mechanism that did not involve modulation of the opioid,
nitric oxide or serotonin systems [66], and; iv) α-amyrin
and β-amyrin, in mixture, exerted significant antinoci-
ception only against the acetic acid-, capsaicin-, glutamate-
and formalin-, but not thermal-induced nociceptive models
in mice. Interestingly, this mixture also exhibited a non-
opioid-mediated antinociceptive activity [67]. As described
above, two reports [66, 67] on the failure of triterpenes to
attenuate thermal-induced nocicpetion seems to contradict
our findings with triterpene-rich PEMM. This discrepancy
could be attributed to the low dose (30 mg/kg) of pure tri-
terpenes used by those authors whereas in the present
study PEMM fraction was effective only at the doses of 250
and 500 mg/kg.
Further analysis using the GCMS method on the
presence of volatile compounds in PEMM revealed the
presence of 29 volatile compounds of which five are the
major compounds, namely, oleoamide (9-octadecenamide)
(11.54%), 23-ethyl- (3β-23S)-cholest-5-en-3-ol (10.06%),
palmitic acid (6.95%), phthalic acid (5.90%) and linolenic
acid methyl ester (5.69%). Of these, at least, oleoamide
and palmitic acid has been reported to show some
pharmacological activities related to the antinociceptive
activity of PEMM. Oleamide, for example, has been re-
ported to exert anti-inflammatory activity when assessed
using the lipopolysaccharide (LPS)-induced BV2 micro-
glial [68]. The inhibition of inflammation occurs via inhib-
ition of NO and PGE2 production. Moreover, oleamide
also inhibits the activation of NFκB and PI 3-kinase, as
well as the phosphorylation of inhibitor κB kinase, Akt,
p38 MAPK, and ERK, and accumulation of reactive
oxygen species (ROS) induced by LPS on BV2 microglial.
On the other hand, Déciga-Campos et al. [69] have
earlier reported on the antinociceptive activity of sev-
eral palmitic acid derivatives, namely N-(4-Methoxy-2-
nitrophenyl)hexadecanamide, 2-amino-3-(palmitoylamino)
benzoic acid or 4-amino-3-(palmi-toylamino)benzoic acid
when assessed using the abdominal constriction and hot
plate tests.
Conclusion
In conclusion, PEMM is suggested to demonstrate the
non-opioid mediated antinociceptive activity at the periph-
eral and central level partly via the modulation of the vanil-
loid receptors, glutamatergic system and NO-mediated/
cGMP-independent pathway. On the other hand, the anti-
nociceptive potential of PEMM might be attributed, in
part, to the presence of oleoamide and palmitic acid, the
volatile compounds with pain relieving activity, as well as
the higher content of triterpenes. Flavonoids, proven to be
presence in low quantity in PEMM via the phytochemical
screening and HPLC analyses, was further supported by
the HPLC-ESI analysis that further shows the presence of
low content of gallocatechin and epigallocatechin, might
work synergistically with tannins and/or saponins, which
also presence in low content, to further enhance the
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antinociceptive action of oleoamide and palmitic acid, and
triterpenes.
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